ProfileGDS5678 / 1423641_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 94% 94% 95% 94% 94% 93% 94% 93% 95% 94% 95% 95% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.1589694
GSM967853U87-EV human glioblastoma xenograft - Control 28.2887994
GSM967854U87-EV human glioblastoma xenograft - Control 38.2703894
GSM967855U87-EV human glioblastoma xenograft - Control 48.6365295
GSM967856U87-EV human glioblastoma xenograft - Control 58.2744894
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.8648494
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.7094893
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.1977794
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.8794293
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.4313995
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.1583194
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.410495
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.3435995
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.2339394